 Home > Active Ingredient News > Drugs Articles > JPM hits Pfizer, Squibb, Eli Lilly, Johnson & Johnson..... Embrace diversification, strong mergers and acquisitions, the year of new drugs!

JPM hits Pfizer, Squibb, Eli Lilly, Johnson & Johnson..... Embrace diversification, strong mergers and acquisitions, the year of new drugs!

 Last Update: 2023-02-01
 Source: Internet
 Author: User

Tags

what bcaa mean

carestream health

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In recent days, the world's attention has attracted the 41st J.
P.
Morgan Annual Meeting (J.
P.
Morgan Healthcare).
Morgan Healthcare Conference, hereinafter referred to as JPM Conference) maintained its popularity
.

At the end of the two years, global pharmaceutical industry leaders, emerging biopharmaceutical companies, innovative technology companies and investors will gather, and about 550 companies and 8,000 attendees will face to face to develop and cooperate with pharmaceutical giants such as Novartis, Johnson & Johnson, Pfizer and other pharmaceutical giants
.

This is the most important week
of the year for the global biopharmaceutical industry.
Major companies took the stage to reveal their next moves, and major investors are also looking for new cooperation opportunities
.
As the world's largest industry event in the field of medical investment, JPM Conference plays an important role
as an industry vane.

In just the past 48 hours, the JPM conference has delivered a lot of new news in the industry
.
Michael, head of global healthcare at JPMorgan Gaito said: "New industry interests are mainly focused on driving integration and services
.
”

After the wave of M&A financing, recession and epidemic crisis in 2022, what new plans and turnarounds will the major pharmaceutical giants have?

Pfizer

19 products launched in the next 18 months

The "national talks" ended, and Pfizer was still in the storm of
public opinion.
At the JPM conference, with the news of the failure of the new crown drug Paxlovid medical insurance negotiations, Pfizer explained Paxlovid's next steps
in China.

Pfizer CEO Albert Bourla said it has no plans to open generic Paxlovid licenses to China, but has reached agreements with Chinese partners to localize Paxlovid production for the Chinese market
.

For Pfizer, although it is difficult to continue the surge in performance based on new crown-related products in the future, this does not mean that Pfizer will enter a dangerous place
.
Albert Bourla predicts that vaccination rates will decline or stabilize above 30 percent next, and Albert Bourla expects the coming wave of outbreaks to be more severe and treatment rates to rise
.

In the current global market downturn, Albert Bourla believes Pfizer has had the most successful year
in its history.
For the future, Albert Bourla is quite optimistic, "I fully believe the best days are yet to come.
"
Albert Bourla disclosed that Pfizer will launch 19 products in the next 18 months and expects non-COVID revenue to reach $84 billion
in 2030.

BMS

Diversify and prepare for the patent cliff

At JPM 2022, BMS delivered the development theme of striving for growth against the backdrop of the patent cliff and announced that it would augment its internal and external innovation pipeline with approximately $50 billion in cash flow between 2022 and 2024
.

This year, Chris is BMS's Executive Vice President and Chief Commercial Officer Boerner went on to elaborate on the company's important steps to overcome the patent cliff, while saying that annual sales growth is expected to be low to single digits
from 2020 to 2025.

The data shows that BMS Revenue for the third quarter of 2022 was US$11.
218 billion, down 3%
year-over-year.
Affected by the expiration of the patent, Revlimid (lenalidomide) and Abraxane (albumin paclitaxel) became BMS The main reason for
the negative growth in Q3.

BMS said diversification is key to its next phase of growth and is launching younger and more diversified portfolios, according to statistics BMS from 2020 to 2022 Nine new drugs
were launched during the year.
In 2022 alone, BMS has 3 new drugs approved by the FDA, including the melanoma drug Opdualag (nivolumab+ relatlimab), hypertrophic cardiomyopathy drug Camzyos (mavacamten) and psoriasis drug Sotyktu (deuterium colexitinib).

In the future, the 6 major product candidates, milvexian, iberdomide, mezigdomide, BMS-986278, repotrectinib and cendakimab, will be its main growth drivers
in the future.
In addition, BMS estimates that from the $74 billion acquisition of Celgene in 2019 to 2030, about 50% of revenue will come from acquisitions
.

Johnson

Denied interest in acquiring Horizon

The JPM conference focused on Johnson & Johnson's integration direction and acquisitions
.

At the end of 2022, Johnson & Johnson announced the acquisition of all outstanding shares
of artificial heart maker Abiomed for $11.
6 billion.
The acquisition is the first major acquisition since Johnson & Johnson announced the divestiture of its consumer health business and one of the
largest acquisitions in Johnson & Johnson's history.

For future acquisition plans, CEO Joaquin Duato again explicitly denied Horizon at the JPM conference Pharma is interested in acquisitions and said Johnson & Johnson has the ability to identify and onboard outside development channel opportunities, but did not disclose more specifics about
the company's acquisition.
Joaquin Duato expects Johnson & Johnson to still generate $60 billion in drug sales
by 2025.
Much of this growth will come from the company's existing portfolio of low-risk assets, such as the multiple myeloma drug Darzalex and plaque psoriasis treatment Tremfya
.

It is understood that Johnson & Johnson plans to spin off the consumer health business in 2023 to focus on the pharmaceutical and medical device businesses
.
Johnson & Johnson has recently submitted plans
to spin off its consumer health business.
According to its filing with the U.
S.
Securities and Exchange Commission (SEC) The documents say the spin-off company, called Kenvue, will include Johnson & Johnson brands
such as Tylenol, Listerlin, Neutrogena and Nicorette.

Wall Street analysts predict that after divesting the consumer health sector, Johnson & Johnson may strengthen the medical business
through acquisitions.
At present, Johnson & Johnson has already begun to act
.

Eli Lilly

Promote the development and launch of five major drugs

At the JPM conference, two Lilly executives called 2023 the year
Big Pharma embraces new models and new drugs.

"We are now busy driving the development and launch
of five major products.
" Patrik, President, Executive Vice President, President of Immunology and Chief Customer Officer of Eli Lilly USA Jonsson revealed 5 new drugs expected to be launched in 2023, covering Alzheimer's disease, immunity, oncology, weight loss and other fields
.

Donanemab, the much-watched Alzheimer's disease drug, is being evaluated in multiple trials, and Eli Lilly is applying for FDA accelerated approval of donanemab
.

In addition, 4 other drugs expected to be available in 2023 include:

Mirikizumab, an immune drug for ulcerative colitis, Lilly expects to be available in the United States in the first half of this year, followed by Europe and Japan
.

Lebrikizumab, which treats atopic dermatitis, is also currently under FDA review and is expected to be available
by the end of 2023.

Small molecule next-generation BTK inhibitor pittobrutinib for patients
with relapsed/refractory mantle cell lymphoma who have previously received BTKi therapy.

The diet drug tirzepatide, a dual GIP/GLP-1 receptor agonist, is currently under phase III evaluation
.
Previously, the drug defeated semeglutide
in head-to-head clinical trials.

Gilead

No major mergers and acquisitions are expected this year

According to live media reports, there was a protest against Gilead outside the JPM conference, criticizing Gilead for doubling
the price of its acquired immunodeficiency syndrome (AIDS) treatment.
The protesters came from the AIDS Health Care Foundation (AHF).

In fact, the AHF has staged several public protests against Gilead to express its displeasure
with the price increase.

Meanwhile at the JPM conference, Gilead Chief Financial Officer Andrew Dickenson says there's still a lot to do and a lot to digest
.
He said Gilead wasn't very eager for big deals in 2023, but that doesn't mean it won't be a deal
this year.
However, even if there is a deal move, it may not be comparable to the large deals that have been reached before
.
For example, in 2020, it acquired Immunomedics for US$21 billion to fill the investment direction of oncology drugs other than hepatitis B, hepatitis C, HIV and other antiviral drugs to drive performance growth
.

Moderna

Revenue from COVID vaccines is expected to exceed $5 billion

On the first day of the conference, Moderna, a manufacturer of new crown vaccines, provided relevant sales data: mRNA new crown vaccine Spikevax generated revenue of about $18.
4 billion last year, down from a previous forecast of $21 billion
.

In its third-quarter earnings report, Moderna lowered its sales forecast for Spikevax to between
$18 billion and $19 billion.
This adjustment takes into account the delay in shipping vaccines
to Europe in response to falling demand.
The company said it has delayed sales of $2 billion to $3 billion of vaccines until 2023
.
CEO of the company Stéphane Bancel said that the industry is more concerned about the sales of new crown vaccines, and expects the minimum sales of new crown vaccines to be about 5 billion US dollars
in 2023.

（Moderna JPM2023 PPT）

Beyond vaccines, Bancel said Moderna is currently developing five latent virus vaccines, each representing a multibillion-dollar market opportunity
.
In the broader use of respiratory diseases, Bancel said its phase III RSV study has met the number of cases needed for the first efficacy analysis, and flu data may be released
this quarter.
Moderna also hopes to launch a Phase III trial
of its mRNA-based cancer vaccine in combination with Merck's Melanoma Keytruda this year.

Currently, Moderna has 48 programs in development, 36 clinical trials underway, and R&D investment will increase to $4.
5 billion
in 2023.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.